{"release":{"schemaVersion":"maha-epistemic-release/1.0","releaseId":"epirelease_06cf4a8617774fb89fcd9f7f8b0d179e","releaseKind":"initial","status":"active","recordId":"urn:maha:record:in-vivo-genome-editing-workflow","domainSlug":"synthetic-biology","targetSha256":"sha256:c04affa4a87aba09a28285d08ee2c933963509ae9064cedf1a66c4dff7cd4dd6","canonicalPath":"/knowledge/synthetic-biology/methods/in-vivo-genome-editing-workflow","canonicalVersion":"1.0.0","supersedesReleaseId":null,"approvals":[{"scope":"boundary-adequacy","reviewId":"epireview_5c816d25de82477e96c29d7b7b25b302","reviewSha256":"sha256:0077864e3cec56b6f68a34398561a0922234b229848bb14cf4db32f9464ff1df","reviewedAt":"2026-08-30T16:02:01.482Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."},{"scope":"domain-fidelity","reviewId":"epireview_7b56c8fad42941dc9fca7ad7b2039511","reviewSha256":"sha256:71137c0e19ff91a429ca305d9c0d6a749c0277c64bd80fd56b292989e0956eb6","reviewedAt":"2026-08-30T16:02:01.416Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."},{"scope":"rights-and-locator","reviewId":"epireview_601eb94d58054e4bb70fb6ce687e5543","reviewSha256":"sha256:79c8df3b246c55865bdae37be89944ac39ae5416d735d54278b5684ab0f8db6f","reviewedAt":"2026-08-30T16:02:01.564Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."},{"scope":"source-fidelity","reviewId":"epireview_9f29035a69144d16adfb4f0928d59e26","reviewSha256":"sha256:8b808c3ce3b6ce9e9762e332716cf9a369ab8ea36782d49a54352a8de21a6fab","reviewedAt":"2026-08-30T16:02:01.349Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."}],"assuranceTier":"internally-reviewed-canonical","releaseAuthority":{"authoritySha256":"sha256:2a0161a3927ae8366af44bda6671b5249802843ff3895dc292c90e5466b88609","attribution":"withheld-by-consent"},"publicChangeSummary":"Initial canonical publication under the disclosed exact-revision internal editorial tier.","recordSha256":"sha256:be7269de29ceb69f04304eac58a054460ee0d667332fa5cde126210fbffb52f9","gateDecision":{"reasons":[],"recordId":"urn:maha:record:in-vivo-genome-editing-workflow","publicEligible":true,"evaluatedAgainst":"maha-epistemic/1.0"},"releasedAt":"2026-08-30T16:02:47.346Z","releaseSha256":"sha256:91af671175e76cac12e763e7e6187f8a808b61961930f2bb7a463e4e78a3d479","withdrawal":null},"provenance":{"schemaVersion":"maha-epistemic/1.0","evidencePolicyVersion":"mps/0.1","recordId":"urn:maha:record:in-vivo-genome-editing-workflow","canonicalPath":"/knowledge/synthetic-biology/methods/in-vivo-genome-editing-workflow","contentHash":"sha256:be7269de29ceb69f04304eac58a054460ee0d667332fa5cde126210fbffb52f9","generatedAt":"2026-08-30T16:02:47.346Z","publicationDecision":{"recordId":"urn:maha:record:in-vivo-genome-editing-workflow","publicEligible":true,"evaluatedAgainst":"maha-epistemic/1.0","reasons":[]},"claims":[{"id":"urn:maha:claim:in-vivo-genome-editing-workflow","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.","boundary":"Early dose-cohort observations do not establish long-term benefit, rare-event safety, repeatability, or transfer to another organ and target.","claimKind":"empirical-claim","sourceIds":["source-gillmore-in-vivo-2021"],"statement":"The cited phase 1 report describes systemic administration, dose cohorts, biomarker response, and early safety observations for a liver-targeted CRISPR intervention.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-gillmore-in-vivo-2021","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2107454","title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Julian D. Gillmore","Ed Gane","Julian Taubel","Jingzhu Kao","et al."],"boundary":"Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.","publisher":"The New England Journal of Medicine","establishes":"The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.","identifiers":[{"value":"10.1056/NEJMoa2107454","scheme":"doi"}],"publishedAt":"2021-06-26","exactLocator":"Abstract; Methods; Results; Figures 1–3; supplementary protocol and statistical analysis.","conflictsOfInterest":"The study was funded by Intellia Therapeutics and Regeneron Pharmaceuticals; author relationships are disclosed."}],"reviewEvents":[{"reviewId":"epireview_9f29035a69144d16adfb4f0928d59e26","scope":"source-fidelity","targetSha256":"sha256:c04affa4a87aba09a28285d08ee2c933963509ae9064cedf1a66c4dff7cd4dd6","reviewedAt":"2026-08-30T16:02:01.349Z","verdict":"approve","supersedesReviewId":null},{"reviewId":"epireview_7b56c8fad42941dc9fca7ad7b2039511","scope":"domain-fidelity","targetSha256":"sha256:c04affa4a87aba09a28285d08ee2c933963509ae9064cedf1a66c4dff7cd4dd6","reviewedAt":"2026-08-30T16:02:01.416Z","verdict":"approve","supersedesReviewId":null},{"reviewId":"epireview_5c816d25de82477e96c29d7b7b25b302","scope":"boundary-adequacy","targetSha256":"sha256:c04affa4a87aba09a28285d08ee2c933963509ae9064cedf1a66c4dff7cd4dd6","reviewedAt":"2026-08-30T16:02:01.482Z","verdict":"approve","supersedesReviewId":null},{"reviewId":"epireview_601eb94d58054e4bb70fb6ce687e5543","scope":"rights-and-locator","targetSha256":"sha256:c04affa4a87aba09a28285d08ee2c933963509ae9064cedf1a66c4dff7cd4dd6","reviewedAt":"2026-08-30T16:02:01.564Z","verdict":"approve","supersedesReviewId":null}]},"privacyBoundary":"Operational actor fingerprints, bearer credentials, private reviewer profiles, affiliations, conflicts, and non-consented authority identity fields are excluded."}